Lilly Endowment Inc. lowered its stake in shares of Eli Lilly and Co (NYSE:LLY) by 0.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,075,804 shares of the company’s stock after selling 405,000 shares during the quarter. Eli Lilly and comprises approximately 100.0% of Lilly Endowment Inc.’s investment portfolio, making the stock its biggest position. Lilly Endowment Inc. owned about 0.11% of Eli Lilly and worth $10,394,982,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of LLY. Coastline Trust Co lifted its stake in Eli Lilly and by 28.0% during the fourth quarter. Coastline Trust Co now owns 14,502 shares of the company’s stock worth $1,225,000 after purchasing an additional 3,175 shares during the last quarter. Koshinski Asset Management Inc. lifted its stake in Eli Lilly and by 20.4% during the fourth quarter. Koshinski Asset Management Inc. now owns 7,644 shares of the company’s stock worth $646,000 after purchasing an additional 1,297 shares during the last quarter. National Pension Service lifted its stake in Eli Lilly and by 4.3% during the fourth quarter. National Pension Service now owns 823,494 shares of the company’s stock worth $69,552,000 after purchasing an additional 33,628 shares during the last quarter. RNC Capital Management LLC lifted its stake in Eli Lilly and by 1.0% during the fourth quarter. RNC Capital Management LLC now owns 465,435 shares of the company’s stock worth $39,311,000 after purchasing an additional 4,832 shares during the last quarter. Finally, E&G Advisors LP bought a new stake in Eli Lilly and during the fourth quarter worth $372,000. 76.35% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have weighed in on the company. Jefferies Group set a $100.00 target price on Eli Lilly and and gave the stock a “buy” rating in a research note on Tuesday. Goldman Sachs Group cut Eli Lilly and from a “buy” rating to a “neutral” rating and upped their target price for the stock from $86.98 to $95.00 in a research note on Tuesday. BMO Capital Markets restated a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a research note on Thursday, September 28th. Cowen restated a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $92.75.
In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders sold a total of 251,088 shares of company stock valued at $22,041,236 over the last quarter. 0.20% of the stock is owned by corporate insiders.
Shares of Eli Lilly and Co (NYSE:LLY) traded down $1.69 on Wednesday, hitting $85.29. The stock had a trading volume of 4,878,300 shares, compared to its average volume of 2,955,040. Eli Lilly and Co has a one year low of $74.00 and a one year high of $89.09. The company has a market cap of $94,930.00, a PE ratio of 40.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the prior year, the company earned $0.88 EPS. Eli Lilly and’s revenue was up 9.0% compared to the same quarter last year. research analysts anticipate that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.64%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is presently 99.05%.
TRADEMARK VIOLATION NOTICE: “Lilly Endowment Inc. Sells 405,000 Shares of Eli Lilly and Co (LLY)” was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://transcriptdaily.com/2018/01/17/lilly-endowment-inc-sells-405000-shares-of-eli-lilly-and-co-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.